Eli Lilly and Company
Industry / private company
Location:
Indianapolis, IN,
United States (USA) (US)
ISNI: 0000000022202544
ROR: https://ror.org/01qat3289
STRUCTURAL DAMAGE PROGRESSION IN PATIENTS TREATED WITH METHOTREXATE, BARICITINIB MONOTHERAPY OR BARICITINIB plus METHOTREXATE BASED ON THEIR LEVEL OF CLINICAL RESPONSE IN THE PHASE 3 RA-BEGIN STUDY (2017)
Van Der Heijde D, Durez P, Schett G, Naredo E, Ostergaard M, Meszaros G, Bello N, et al.
Conference contribution
Exploratory Analysis to Identify Factors Associated with Risk of Structural Progression, Defined As Change from Baseline (2017)
Van Der Heijde D, Durez P, Schett G, Naredo E, Ostergaard M, Meszaros G, Lopez-Romero P, et al.
Conference contribution
Systems biology of the IMIDIA biobank from organ donors and pancreatectomised patients defines a novel transcriptomic signature of islets from individuals with type 2 diabetes (2017)
Solimena M, Schulte AM, Marselli L, Ehehalt F, Richter D, Kleeberg M, Mziaut H, et al.
Journal article
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma (2016)
Crump M, Leppa S, Fayad L, Lee JJ, Di Rocco A, Ogura M, Hagberg H, et al.
Journal article
Robustness of automated hippocampal volumetry across magnetic resonance field strengths and repeat images (2014)
Wolz R, Schwarz AJ, Yu P, Cole PE, Rueckert D, Jack CR, Raunig D, Hill D
Journal article
Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (2013)
Wick W, Steinbach JP, Platten M, Hartmann C, Wenz F, Von Deimling A, Shei P, et al.
Journal article
Frailty and sarcopenia: definitions and outcome parameters (2012)
Cooper C, Dere W, Evans W, Kanis JA, Rizzoli R, Sayer AA, Sieber C, et al.
Journal article